Did you know that, according to the National Cancer Institute, close to 40% of individuals of both sexes could receive a cancer diagnosis in their lifetime? Fortunately, the co-founder and CEO of Seattle Genetics is on the job, furthering the development of therapeutic pharmaceuticals for treating a number of diseases with extremely high mortality rates, like cancer.
Cancer Research Leader
Seattle Genetics has been busy since its startup in 1998, achieving major status in the field of cancer research. It has become an innovative research leader in the development and marketing of new cancer drugs that utilize antibody-based therapies for expanding the available treatment options. This emerging oncology biotechnology company is also leading the industry via its proprietary technology that they’ve been using to develop stable and potent antibody-drug conjugates (ADC). These ADCs have the capability for providing improved results for many cancer patients and especially those who need it the most.
ADCs for Treating Lymphomas
The ADCs from Seattle Genetics are effective for treating lymphomas like Hodgkin’s lymphoma. This type of cancer is responsible for approximately 8,000 new cases annually, mainly affecting young people and targeting white blood cells, as well as their immune systems. In addition, the Seattle Genetics’ ADCs are being used for treating non-Hodgkins lymphoma cases, which represent 70,000+ diagnoses per year, most of which affect the elderly.
Good-bye to Chemotherapy
As the CEO and founder of Seattle Genetics, Dr. Clay Siegall, has been in charge of developing targeted therapy drugs for the treatment of some diseases that haven’t been experiencing any substantial improvements in 20 years or more in their respective mortality rates. He holds a George Washington University Ph.D. in genetics and a zoology B.S. from the University of Maryland. He is also a firm believer that chemotherapy is definitely destined for extinction since targeted therapies are increasing in both efficacy and value and old therapies will soon be systematically replaced by targeted drugs that are much more effective and easily tolerated by patients. And, research at Seattle Genetics is also ongoing toward achieving ADC breakthroughs in treating acute myeloid leukemia